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There is now a substantial number of studies on
the radiotherapy for head and neck cancer using
altered fractionation schedules, and nearly all
prove an increased incidence and severity of
acute mucosal reactions. Thus, when one
considers alternative fractionation strategies,
acute mucosal reactions become the most
significant dose-limiting regardless of radiation
quality because mucosa is very sensitive to the
accumulated dose per week (AD) and each of
these schedules involves a higher AD than that in
conventional treatment [Peters et ai, 1991;
Thames et al. 1990; Withers et ai, 1989]
Clinical data selection
Incidence and kinetics of acute and late
radiation effects in normal tissues are discussed
based on the analysis of 25 clinical data sets
taken from the literature [Ang, 1990; Dische,
1981; Fletcher et ai, 1962; Horiot et al,1988;
Horiot et ai, 1992; Johnson et ai, 1992; Kaanders
et al 1992; Kneeet ai, 1985; Karin et ai, 1987;
Lamb et ai, 1990; Maciejewski et ai, 1995;
Maciejewski et ai, 1991; Marcial et ai, 1987; Moez
et ai, 1984; Nguyen et al 1985; Olmi et ai, 1990;
Parsosn et al 1998; Peracchia and Salti, 1981;
Saunders et ai, 199,1; Svoboda 1984; Van der
Schueren et ai, 1990; Wang et ai, 1985; Wang
1988; Wendt et al 1989]. The raw data were
available for a few studies, but in most cases data
were taken from reports in the literature.
RESULTS AND DISCUSSION
Accumulated dose/week (AD) vs incidence
and severity of acute mucositis
In conventional radiotherapy given in 1.6-2.0 Gy
fractions up to a total dose of about 70 Gy,
confluent mucositis (CM) is generally reached at
day 22. The threshold for the CM appears to be
around 20 Gy and the CM usually develops about
9 days after delivering that dose. However, some
studies suggest that the onset of CM may depend
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on the accumulated dose/week and the larger AD
is the sooner CM is reached.
All these observations suggest that the intensity
of acute epithelial reactions, and likely other H-
type-like tissues reflect the balance between the
rate of cell killing by irradiation and the rate of
regeneration of the surviving stem cells. Once a
critical level of survival cells has been attained, a
certain type of clinical damage will develop at a
rate only determined by the cellular kinetics of the
tissue. When a peak in the CM is reached, further
stem cell killing cannot produce an increase in the
intensity of acute reactions, but could be
manifested as prolonged time to heal the
reactions. In the Van der Schueren [Van der
Schueren E. et ai, 1991] study a splitcourse
irradiation was used, and even concentrated
multiplefractions per day (MFD) schedules (Tab.1
Scheme I-III)
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Table I. Incidence of confluent mucositis (SCM) and
consequential late effects (CLE) in accelerated fractionation.
(AD/wk - accumulated dose per week; DTR - Dose-Time Ratio)
with a high AD did not change the time and rate
of the CM development and did not produce
prolonged confluent mucositis; in fact the duration
of CM was shorter than in conventional treatment,
and they healed completely during 2-3 week
breaks in the treatment.
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Table III. Incidence of acute mucositis (CM) and true late
effects (TLE) in hyperfractionation.
(AD/wk - accumulated dose per week; DTR - Dose - Time
Ratio)
Parsons 12Gy 74.4·79.2/42d 2.61 20% 5%
88
Wendl 12Gy 72·80.6Gy142·49d 2.45 25%89 5%
Moez.84 12Gy 60·75Gy/35·4Sd 2.44 22% 17%
COll.90 12Gy 67.2·168GyI38·44d 2. S 4 41% 10%
For hyperfractionated treatments (tab.lIl) where
the DTR was in the range of 2.44-2.61 Gy/dal
and the AD was about 11-12 Gy the incidence of
confluent mucositis was between 22% and 60%.
For predominantly accelerated treatments (Tab.II),
an increase of the AD to 14-18 Gy, even when
DTR was in similar range as for
hyperfractionation, leads to the increased
incidence of CM, in the range from 58% to 91 %.
Drastic reduction with the treatment time to 9-14
days in purely accelerated treatments resulted in
the AD above 25 Gy, and the DTR in the range
5014 Gy x dai2 producing presistent confluent












Accelerated and hyperfractionated schedules
The analysis· of the sets of data of accelerated,
predominantly accelerated and hyperfractionated
radiation treatments shows that, except for
hyperfractionation and short single course
accelerated regimens, the AD is not constant in
consecutive weeks of treatment. High AD, above
25 Gy is typical for accelerated treatments when
the dose is condensed into a single course in a
short overall treatment time. In concomitant boost
schedule [Ang et ai, 1990; Peters et aI, 1991] a
high AD of 16.5 Gy is delivered either in each of
the first or/of the last two weeks of treatment and
in the remaining weeks it is not higher than 9 Gy.
In double-BID-split course schedule [Van der
Schueren et ai, 1990; Wang et ai, 1985] the AD of
16 Gy is given in the first 2.5 weeks and in the last
1.5 week separated by 2-3 weeks break. In so-
called escalated fractionation [Kaanders et ai,
1992; Maciejewski et ai, 1992] the AD increases
from 14-15 Gy to 18 Gy in the last two weeks of 5-
week treatment.
It seems that it is not easy or even impossible at
least for some schedules to express the AD for a
given treatment with a single value, and this could
have an important impact on the onset and
intensity of confluent mucositis. For that reason,
an additional factor: Dose-Time Ratio (DTR) was
introduced in the analysis. In general, it is the ratio
of Dose Intensity (Dl=DIT), and then it can be
written as
where: DTR is an average dose/day x average
fractions/day and it is quantified in Gy/daj. For 60
Gy in 30 fractions during 42 days, and for 70 Gy in
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Figure 1. The onset of confluent mucositis depending on
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Table II. Incidence of confluent mucositis (SCM) and
consequential late effects (CLE) in predominanty accelerated
fractionation.(AD/wk - accumulated dose per week; DTR - Dose
-Time Ratio)
o+-'-r---.--,~,.......~==;;==;=::;:::=;;::;:!
6 10 14 18 22 26 30 34
ACCUMULATED DOSElWEEK in Gy
Figure 2. Incidence of confluent mucositis depending on
accumulated dose per week.
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Figure 3. Incidence of confluent mucositis depending on
Dose-Time Ratio.
Figure 2 and Figure 3 show that both the
accumulated dose/week (AD) and the Dose-Time
Ratio (DTR) correlate with the incidence of severe
confluent mucositis (CM). It has to be pointed out
that if the AD is higher than 20 Gy and the DTR
increases above 6 Gy/da{- healing of the CM was
always delayed and consequential late necrosis
has often occured as a consequence of severe
epithelial denudation. If in the irradiated area
epithelial stem cells are deeply or completely
depopulated, and the healing, if it occurs, is
delayed, infection and/or trauma can lead to
secondary damage to subjacent normal tissues
and this type of necrosis occurs as a
consequence of a severe acute reaction. A typical
example of this phenomenon in of 55% cases of
non-healing confluent mucositis leading to
mucosal
necrosis was observed by Peracchia [Perachcia
et aI, 1981] after 50-54 Gy delivered in 9-11 days
of accelerated treatment. For this treatment the
AD was 30 Gy and the DTR was 14.2 Gy x day·2.
Suprisingly, typical consequential necroses in
30% of patients were observed by Maciejewski et
al [Maciejewski et ai, 1995] when 70 Gy in 35
fractions (1 daily fraction) was delivered in 35 days
(7days per week treatment) instead of 49 days.
Although the AD was 14 Gy and the DTR was as
low as 2.0 Gy/da{- , soft tissue necrosis or
osteoradionecrosis occured.
Oral mucosa classified as rapidly proliferating
tissue is capable of compensating for cell killing
induced by 1.8 Gy/day towards the end (probably
not the begining) of a 6-week treatment. The cells
surviving an irradiation of oral mucosa are likely to
rapidly lose any latent damage and react as if they
had not been irradiated. They probably need very
little time for recovery and when the subsequent
irradiation is given no cumulative effects are seen
[Van der Schueren et ai, 1990]. This suggestion
mainly comes from the studies when the AD was
high but only for a short period of 1-2 weeks and it
was followed by low AD (10 Gy) in consecutive
weeks or was separated by a 2-3 week break.
Seven-day treatment without weekend-breaks,
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even when conventional fraction of 2 Gy was
repeated in 24-hour intervals, led to an
unacceptable risk of consequential effects. It
seems that constant AD of 14 Gy through out 5
consecutive weeks of treatment could make cell
proliferation not effective enough to compensate
for radiation cell killing. In consequence, gradual
denudation of epithelial stem cells resulted in early
necrosis which occured 2-10 months after the
treatment.
Assuming that the TRU (tissue rescuing unit) for
mucosa is 1 stem cell per 1/10cm2 area to avoid
persistent confluent mucositis and consequential
necrosis [Withers et ai, 1988], the observed
effects in 30% case of early mucosal necrosis
may suggest that cell survival was on average
less than 7 cells per 1 cm2. Thus, only less than
7/10 of the given dose was effectively
compensated for by repopulation of mucosal stem
cells which may suggest Dpmfil of about 1.1-1.2 Gy
per day, which is less than the value generally
assumed for conventional fractionation
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Figure 4. The time of complete healing of confluent mucositis
depenging on accumulated dose per week.
If more than 7 stem cells per 1 cm2 of mucosa
survive irradiation and/or migration of epithelial
cells from the periphery is not affected by infection
or trauma, it seems that the time of the complete
healing of acute mucositis depends on the AD
(Fig.4). If the AD is higher than 14 Gy complete
healing can even be prolonged to 20 weeks after
treatment.
CONCLUSIONS
When fractionation regimens are altered to
achieve a therapeutic gain through an increased
tumour response relative to late normal tissue
response, acute mucosal reactions become dose
limiting in radiotherapy for head and cancer.
An acceptable risk of acute mucositis can be
expected when the Dose-Time Ratio (DTR) is
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lower than 2.5 Gy x day -2 and the accumulated
dose per week (AD) is less than 12 Gy. Higher AC
can only be considered if it is administered in no
more than 2 consecutive weeks of 5-6 week
treatment or a 2-3 week split is given between
series of high AD (or DTR).
A high constant value of the AD (>14 Gy) during
5-6 weeks of treatment or the AD above 20 Gy
and DTR above 10 Gy x day-2 lead to a high risk
of persistent confluent mucositis and
consequential late necrosis which may occur
within 4-8 months after treatment.
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